Does Shire Have The Strategy To Deliver On Rare Opportunity In Early/Mid Pipeline?
Executive Summary
The biotech laid out its pipeline during a Dec. 10 R&D day in hopes of convincing analysts and investors that its rare disease focus will pay off in coming years.
You may also be interested in...
Sanofi Should Take Note: Insiders Might Just Make Better CEOs
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.
Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less
Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.
Searching For Surrogate Endpoints Requires Teamwork
Discussions between FDA and researchers during a workshop on the fatty liver conditions NAFLD/NASH clarified the status of potential surrogate endpoints for clinical trials, but indicated that much work remains to be done to ready the various options for use – and that will likely need to be a joint effort.